Zelf geld lenen via crowdfunding?
  

Logo

The concept Potential investors should read this summary as an introduction to the investment memorandum. Every decision to invest should be based on studying the full investment memorandum, including the attachments Summary convertible bond issuance Issuing entity: NLC Ventures Netherlands B.V. Website: http://www.nlc.nl Type of issuance: Convertible bond Issuance amount: Up to max € 1.000.000,- with a minimum of €500.000,- Minimal nominal value per participation: € 20 Use of funds: The issuer will use the proceeds from the security to finance the process of scouting, selecting, validating and building new ventures Risk profile: High (Click here for more information on Symbid risk profiles) Interest rate: 8,0% (flat rate, accrued) Secured: None Duration: 3 years conversion period 2 years automatic conversion period 2 years possible extension of automatic conversion period Repayment: After duration period has ended (5-7 years) Possibility for early repayment: Yes, with mutual consent Compensation early repayment: None Conversion: Under certain circumstances you can convert to shares of NLC Ventures Netherlands B.V. or one of its portfolio companies Symbid costs issuing entity: 2,5% success fee (Excl. VAT) Symbid costs investor: 0% administration fee (Excl. VAT) NLC is the European healthtech venture builder, bringing science-based healthtech inventions to life. The company was founded in 2014 based on one simple observation: due to market complexities and silos at least 95% of healthtech inventions never reach society, regardless of their relevance and genius. We all know stories from our family, friends, and colleagues about people with life-impacting health issues. Whether it is cancer, heart disease, miscarriage, stroke, asthma, COPD, diabetes, Alzheimer’s or any other disease. Sometimes, those stories feel far away; sometimes, they come painfully close. It is hard to believe that we still accept that scientific inventions do not reach our most loved ones, even though we know they are there. At NLC, we don’t accept this status-quo. We take responsibility and act. We call this opportunity. We bring together the best tech, the best people, and the best capital to build life-changing healthtech ventures. We cross barriers. We have designed a bold model to create early stage healthtech innovation. We step in when inventors need us most. We can step in because our model and mission are fully aligned to bring science to life. Our multilingual team is able to speak the languages of the many different silos. We build healthtech ventures, together with leading European research institutes, top-notch hospitals, innovative SME’s, global market leaders and the whole range of service providers. Together, we fulfil our mission to bring science to life. I would like to invite you to embark on this journey with us. Unique Selling Points The Health Impact Bond provides unique access to a diversified portfolio of early stage healthtech ventures Investors can convert to equity each time an external financing round takes place Cherry picking the most promising ventures exposes investors to a diversified portfolio, tailored to their personal preferences 8% flat rate interest until conversion Revenue model Our venture building model focuses on creating value and capturing it at the right moment We get involved before inception, when potential to create value is highest During our building process, we add value by creating robust business models, unlocking the full potential of an invention We secure capital for growth at different stages of venture maturity We exit our ventures when they are ready to be transferred to a strategic partner or professional investor Investors can now invest in NLC and it’s most successful healthtech ventures through a convertible bond The Health Impact Bond acts as a loan up to conversion, and as equity afterwards A conversion opportunity arises when a qualified financing has been made in NLC or one of our qualified ventures After a qualified financing has been made, investors can opt for conversion Return on investment depends on the time to conversion, the share price development after conversion, and the time to exit Investors get three years to convert the Health Impact Bond into equity, after that, a phase out period triggers automatic conversion Achieved so far As to date, we have scouted over 2,500 tech leads, and built 16 ventures. NLC has a proven track record and developed a methodology to scout, select, validate, build and scale up promising healthtech inventions that have the potential to improve quality of life for patients. NLC focuses on evidence-based inventions and therefore partners with universities, academic hospitals, research centers, Medical specialistic companies, and corporates. Required investment and purpose NLC uses the proceeds to scout, select, validate and build early-stage healthtech ventures, and extend its portfolio. General risks of investing in SME’s Negative impact through changes in rules and regulations by political decisions Changes in macro-economic conditions Performance of issuing entity is dependent upon functioning of board members Tax risks through changes in regulations, new regulations or political decisions Company specific risks NLC is operating in a highly competitive market with associated risks NLC is not able to find the right leads/propositions NLC does not succeed in contracting these propositions NLC is not successful in transforming propositions into commercially viable companies NLC's portfolio companies are not successful in securing sufficient financing NLC is not successful in meeting its obligations and is therefore not able to provide value adding services to its portfolio companies NLC is not successful in generating cash flow through the sale of equity it holds in portfolio companies to cover its own operational costs and/or obligations. Risks while investing through convertible bonds Loss of capital Lender issues a (subordinated) convertible loan to convert at a later stage to depository receipts to become a shareholder of the company (or one or more of its portfolio companies). Lender expects an (exponential) growth of value of the company with the possibility to sell the depository receipts with a capital gain. However, in most situations such capital gains do take more than an additional five years after conversion to be realized. In exchange for the possibility of a high return in case of a scenario of exponential growth of the value of the company, there is a risk the investment will be lost in case the company is not doing well. Subordination of loan The lender agrees that its claims against the borrower under the convertible loan agreement used on the Symbid platform rank below all other, non-subordinated, claims against the Lender as referred to in Section 3:277.2 Dutch Civil Code (‘BW’). Limited tradability The convertible bonds can not be traded on a platform or a stock market and are therefore limited tradable. This means there is a chance that there is no buyer for the bond if investor wants to sell his bond and investor has the risk that he needs to continue his investment longer or sell for a lower price. Please be informed further on our general risk page about the risks as outlined above and find out more on our default reporting before you start investing.

Investeer snel en eenvoudig op het platform met
het grootste aanbod van Nederland.
Projectnaam NLC - Health Impact Bond
Projectlink Ga naar project
Plaatsingsdatum 12-04-2018
Type financiering Converteerbare lening
Streefbedrag € 1.260.000
Rente 0,00%
Looptijd (in maanden) 0 maanden
Branche Gezondheidszorg
Organisatievorm Besloten vennootschap
Ontwikkelfase Groei
Doel van investering Werkkapitaal

The concept Potential investors should read this summary as an introduction to the investment memorandum. Every decision to invest should be based on studying the full investment memorandum, including the attachments Summary convertible bond issuance Issuing entity: NLC Ventures Netherlands B.V. Website: http://www.nlc.nl Type of issuance: Convertible bond Issuance amount: Up to max € 1.000.000,- with a minimum of €500.000,- Minimal nominal value per participation: € 20 Use of funds: The issuer will use the proceeds from the security to finance the process of scouting, selecting, validating and building new ventures Risk profile: High (Click here for more information on Symbid risk profiles) Interest rate: 8,0% (flat rate, accrued) Secured: None Duration: 3 years conversion period 2 years automatic conversion period 2 years possible extension of automatic conversion period Repayment: After duration period has ended (5-7 years) Possibility for early repayment: Yes, with mutual consent Compensation early repayment: None Conversion: Under certain circumstances you can convert to shares of NLC Ventures Netherlands B.V. or one of its portfolio companies Symbid costs issuing entity: 2,5% success fee (Excl. VAT) Symbid costs investor: 0% administration fee (Excl. VAT) NLC is the European healthtech venture builder, bringing science-based healthtech inventions to life. The company was founded in 2014 based on one simple observation: due to market complexities and silos at least 95% of healthtech inventions never reach society, regardless of their relevance and genius. We all know stories from our family, friends, and colleagues about people with life-impacting health issues. Whether it is cancer, heart disease, miscarriage, stroke, asthma, COPD, diabetes, Alzheimer’s or any other disease. Sometimes, those stories feel far away; sometimes, they come painfully close. It is hard to believe that we still accept that scientific inventions do not reach our most loved ones, even though we know they are there. At NLC, we don’t accept this status-quo. We take responsibility and act. We call this opportunity. We bring together the best tech, the best people, and the best capital to build life-changing healthtech ventures. We cross barriers. We have designed a bold model to create early stage healthtech innovation. We step in when inventors need us most. We can step in because our model and mission are fully aligned to bring science to life. Our multilingual team is able to speak the languages of the many different silos. We build healthtech ventures, together with leading European research institutes, top-notch hospitals, innovative SME’s, global market leaders and the whole range of service providers. Together, we fulfil our mission to bring science to life. I would like to invite you to embark on this journey with us. Unique Selling Points The Health Impact Bond provides unique access to a diversified portfolio of early stage healthtech ventures Investors can convert to equity each time an external financing round takes place Cherry picking the most promising ventures exposes investors to a diversified portfolio, tailored to their personal preferences 8% flat rate interest until conversion Revenue model Our venture building model focuses on creating value and capturing it at the right moment We get involved before inception, when potential to create value is highest During our building process, we add value by creating robust business models, unlocking the full potential of an invention We secure capital for growth at different stages of venture maturity We exit our ventures when they are ready to be transferred to a strategic partner or professional investor Investors can now invest in NLC and it’s most successful healthtech ventures through a convertible bond The Health Impact Bond acts as a loan up to conversion, and as equity afterwards A conversion opportunity arises when a qualified financing has been made in NLC or one of our qualified ventures After a qualified financing has been made, investors can opt for conversion Return on investment depends on the time to conversion, the share price development after conversion, and the time to exit Investors get three years to convert the Health Impact Bond into equity, after that, a phase out period triggers automatic conversion Achieved so far As to date, we have scouted over 2,500 tech leads, and built 16 ventures. NLC has a proven track record and developed a methodology to scout, select, validate, build and scale up promising healthtech inventions that have the potential to improve quality of life for patients. NLC focuses on evidence-based inventions and therefore partners with universities, academic hospitals, research centers, Medical specialistic companies, and corporates. Required investment and purpose NLC uses the proceeds to scout, select, validate and build early-stage healthtech ventures, and extend its portfolio. General risks of investing in SME’s Negative impact through changes in rules and regulations by political decisions Changes in macro-economic conditions Performance of issuing entity is dependent upon functioning of board members Tax risks through changes in regulations, new regulations or political decisions Company specific risks NLC is operating in a highly competitive market with associated risks NLC is not able to find the right leads/propositions NLC does not succeed in contracting these propositions NLC is not successful in transforming propositions into commercially viable companies NLC's portfolio companies are not successful in securing sufficient financing NLC is not successful in meeting its obligations and is therefore not able to provide value adding services to its portfolio companies NLC is not successful in generating cash flow through the sale of equity it holds in portfolio companies to cover its own operational costs and/or obligations. Risks while investing through convertible bonds Loss of capital Lender issues a (subordinated) convertible loan to convert at a later stage to depository receipts to become a shareholder of the company (or one or more of its portfolio companies). Lender expects an (exponential) growth of value of the company with the possibility to sell the depository receipts with a capital gain. However, in most situations such capital gains do take more than an additional five years after conversion to be realized. In exchange for the possibility of a high return in case of a scenario of exponential growth of the value of the company, there is a risk the investment will be lost in case the company is not doing well. Subordination of loan The lender agrees that its claims against the borrower under the convertible loan agreement used on the Symbid platform rank below all other, non-subordinated, claims against the Lender as referred to in Section 3:277.2 Dutch Civil Code (‘BW’). Limited tradability The convertible bonds can not be traded on a platform or a stock market and are therefore limited tradable. This means there is a chance that there is no buyer for the bond if investor wants to sell his bond and investor has the risk that he needs to continue his investment longer or sell for a lower price. Please be informed further on our general risk page about the risks as outlined above and find out more on our default reporting before you start investing.

Bron: Symbid d.d. 12-04-2018 Disclaimer: De beschrijving is letterlijk overgenomen van bovenstaande Bron en (eventueel) gecorrigeerd voor Persoonsgevens. Beek & Linden B.V. kan niet aansprakelijk worden gehouden voor de inhoud van deze beschrijving. Eigenaar van het project kan via Crowdfundmarkt een verzoek indienen om de beschrijving te verwijderen van deze pagina.

Platform Symbid
Platformlink Ga naar Symbid
Oprichtingsjaar platform 2011
Minimum investeringsbedrag € 20 per project
Investeringskosten Eenmalige administratie 1,0% van uw investering; per transactie kosten van de bank

Lening - 6,00%

€110.000 / €500.000

Oneplanetcrowd

Lening - 9,49%

€12.900 / €30.000

Funding Circle

Lening - 7,00%

€300.000 / €1.200.000

Oneplanetcrowd

Converteerbare lening

€520.000 / €2.000.000

Oneplanetcrowd

Lening - 14,99%

€8.100 / €45.000

Funding Circle